Introduction
On 2 Jan. 1988, The Lancet published a letter entitled 'Vancomycin-resistant enterococci' written by Anne Uttley from Dulwich PHL in collaboration with Robert George and colleagues then working in the Antibiotic Reference Unit at the Central Public Health Laboratory [I] . This was the first published report of enterococci resistant to high-levels of the glycopeptide antibiotics, vancomycin and teicoplanin. Enterococci showing similar resistance had been reported at the 1987 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [2] and this work was published on 21 July 1988 in the New England Journal of Medicine by Roland Leclercq, Patrice Courvalin and colleagues from Paris [3] . These two publications heralded the arrival in clinical microbiology of vancomycin-resistant enterococci (VRE), although it is more appropriate to refer to these bacteria as glycopeptide-resistant enterococci (GRE); the latter acronym will be used here. Recognition of GRE made clinicians and microbiologists aware that glycopeptides could no longer be relied upon to provide a last line of defence against serious infections caused by gram-positive bacteria. Since then, the lack of reliable therapeutic alternatives for serious gram-positive disease has remained a major driving force for the academic and clinical research that has been undertaken into glycopeptide resistance. In the last decade, understanding of glycopeptide resistance has increased greatly, but the clinical importance of GRE for hospital patients has been and will, no doubt, continue to be debated. Cynics argue that relatively few clinical isolates of GRE (in comparison with, e.g., isolates of methicillin-resistant Staphylococcus aureus, MRSA) have given many researchers a steady supply of publications. However, for others, GRE are a serious concern, especially when they cause life-threatening disease, such as endocarditis; indeed, multiple antibiotic resistance means that some GRE strains are 'untreatable' with almost all currently licensed agents. Hence, a detailed understanding of their epidemiology and ability to disseminate resistance, not only to other enterococci but also to other genera, may allow development of rational infection control policies. This review aims to provide an overview of knowledge of GRE and to highlight areas of current and future research.
Classes of glycopeptide resistance
Four phenotypic classes of GRE are currently recognised (Table 1) [4-111. The first isolates of GRE were from hospital patients in 1986 and were highly resistant to vancomycin (MIC 2 256 mg/L) and cross-resistant to teicoplanin (MIC 2 128 mg/L).
These isolates exhibited what is now known as the VanA resistance phenotype and, while most VanA enterococci continue to display high-level vancomycin resistance, the levels of resistance displayed to teicoplanin are now more varied, with many isolates showing lower levels of resistance (MIC 8-32 mg/L). Most VanA enterococci are isolates of Enterococcus faecium, but this phenotype occurs also in E. faecalis and occasionally in E. avium, E. casselzjlavus, E. durans, E. gallinarum and E. rafinosus [12] . This form of resistance is transferable, in association with plasmids and transposons (Table l) , so its recognition in species other than those named would not be surprising. Indeed, transfer of VanA resistance to nonenterococcal bacterial species, including S. aureus, has been demonstrated in vitro [13, 141 , and VanA resistance has also been documented in occasional clinical isolates of other genera [15, 161. A second class of resistance was reported at the 1987 ICAAC meeting [17] and again in 1989 [18, 191 . It was associated with low levels of vancomycin resistance (MICs of 16-64 mg/L), but sensitivity to teicoplanin (MIC d 4 mg/L). This VanB phenotype is found predominantly in E. faecalis and E. faecium, but has also been observed in rare isolates of other enterococcal species, including E. casselzjlavus (personal unpublished observation). It is now recognised that the MICs of vancomycin for enterococci expressing VanB resistance vary among isolates (usual range 8-1024 mg/L), but teicoplanin sensitivity remains typical for almost all enterococci with this phenotype [22] . Recently, a fourth phenotype, VanD, has been described in a single strain of E. faecium [4] . It is distinguishable from the VanB phenotype most readily by determination of genotype (see below), although studies of the growth characteristics of the isolate in the presence and absence of glycopeptides to determine the form of resistance expression may also be appropriate (Table 1) .
Detecting glycopeptide resistance in enterococci
The ability of the clinical laboratory to detect a strain of GRE accurately is an obvious requirement for all subsequent studies. However, this fundamental step remains problematic in many instances. Most laboratories test vancomycin primarily, but even isolates of the same resistance phenotype may display varying levels of vancomycin resistance ( More accurate detection and reporting of the various forms of glycopeptide resistance should be a goal for all laboratories, as it is a prerequisite for controlling the spread of resistance [26] . Hence, once vancomycin resistance is confirmed in an isolate, the laboratory should also be able to report confidently its glycopeptide resistance phenotype. A general scheme that may be used to assign these phenotypes is presented in Fig.  1 casselzJ-avus are located on the chromosome and are not transferable. The location of the vanD ligase gene has not been reported yet [4] although, by analogy with VanA and VanB resistance, VanD enterococci with plasmid-mediated and chromosomal genes would be anticipated.
A requirement for multiple gene products
In contrast to mechanisms that confer resistance to most other classes of antimicrobials, glycopeptide resistance does not depend solely on the product of one gene. Although the ligase-encoding genes are necessary to produce the altered peptidoglycan precursors, they are not sufficient to confer phenotypic glycopeptide resistance upon a cell. Expression of resistance depends on the presence of two further essential genes, designated vanH and vanX (in VanA strains) or vanHB and vanXB (in VanB strains). The vanH/vanHB genes encode enzymes that convert pyruvate to D-lactate [48-501 and so make this molecule available to the vanA-and vanB-encoded ligases. As VanA and VanB are acquired resistances, the pathway for producing glycopeptide-resistant peptidoglycan precursors is additional to the native chromosomally encoded, glycopeptide-sensitive path.
This chromosomal pathway appears not to be switched off when resistance is expressed, and so sensitive precursors terminating in D-ala-D-ala are still produced. The products of the vanX/vanXB genes are dipeptidases and are essential for cleaving the D-ala-D-ala dipeptide to prevent its incorporation into precursors [50, 511. In addition to the vanHAXgenes, the VanA transposon Tn1546 also has two other accessory, but non-essential van genes located downstream of the essential region ( Fig. 2) [ 10, 271; van Y encodes a penicillin-insensitive carboxypeptidase [52, 531 and v a n 2 encodes an uncharacterised product that confers low-level teicoplanin resistance [54] . The VanB element Tn1547 also encodes a carboxypeptidase (the product of the van& gene) and carries a gene (vanW) with no homologue in the vanA cluster; the product of vanW has unknown function [SO] . However, on Tn1547, vanYB and vanW are both located between the regulatory genes (see below) and the vanHBBXB essential genes (Fig. 2 ) [50] . The position of these two genes upstream of the essential genes suggests that they may play a more significant role in the expression of VanB resistance than that played by vanY and van2 in VanA resistance.
Regulation of resistance
One of the first observations made regarding VanA and VanB enterococci was that their resistance was inducible in the presence of glycopeptides [18, 55, 561 . Considering only those glycopeptides available for clinical use, VanA resistance is induced by exposure to vancomycin or teicoplanin, whereas VanB resistance is induced only following exposure to vancomycin. It is now understood that the two resistance gene clusters both include genes that encode a two-component regulatory system [50, 571. The products of the v a n s (in VanA strains) and van& (in VanB strains) genes are transmembrane peptides that sense environmental glycopeptides and autophosphorylate in response to their presence [50, 571. Phosphoryl groups are rapidly transferred from the sensors to the products of the vanR or vanRB genes and, in their phosphorylated forms (phospho-VanR or phospho-VanRB), these proteins bind to specific promoter sites within the vanA [58] [68, 691 . The presence of two pathways for the synthesis of peptidoglycan precursors in GRE led to the suggestion that dependent strains had defective D-ala-D-ala ligases and were unable to synthesise normal peptidoglycan. However, in the presence of a glycopeptide, the alternative pathway (D-ala-D-laC) is induced, allowing peptidoglycan synthesis and cell growth [27] . This hypothesis has been confirmed for two isolates [61, 701 . The clinical relevance of dependent strains has been debated and they have been described as 'superbugs' [7 11. However, in the author's opinion, they are defective GRE and should cause no more concern than GRE, except that they may not be detected by standard culture techniques [63, 66, 671 .
The epidemiology of GRE in hospitals
Although studies of the pathogenicity of enterococci are not numerous [72, 731 , with E. faecium rarely included, GRE appear to be no more virulent than glycopeptide-sensitive strains. Moreover, many patients have been colonised, rather than infected. Furthermore, the patients affected frequently have serious underlying disease, and so a poor outcome cannot always be attributed directly to the presence of GRE.
The UK situation Five epidemic vancomyc in (g 1 y c opep t i de) -re s i s tan t strains of E. faecium (EVREM) have been defined on the basis of (i) the macrorestriction digestion patterns of their genomic DNA following separation by pulsed-field gel electrophoresis (PFGE), and (ii) by isolation from at least two patients in at least two hospitals [74] . At present, the strain designated EVREM-3 is causing greatest concern. It is usually multi-resistant, with the VanA phenotype and additional high-level resistance to aminoglycosides, penicillins and numerous other antibiotic classes. It can spread rapidly within a unit and, up to Aug. 1996, had been isolated at 16 hospitals, mostly in the London area. The appearance of EVREM-3 in one hospital outside London could be attributed to the transfer of two patients from a London teaching hospital known to have the strain [75] . The recognition of strains, such as EVREM-3, lends weight to the suggestion that some strains of enterococci (including GRE) 'have heightened capabilities to colonise, overgrow, invade host tissues and persist compared with endogenous enterococcal flora' [ 721.
With the exception of the EVREM strains, analysis by PFGE of the GRE isolated from patients at different UK hospitals reveals marked heterogeneity. Sporadic isolates tend to have unique banding patterns and, although each hospital with a cluster of cases may have a predominant strain, the predominant strains from different hospitals are usually distinct. Given the distribution of affected hospitals throughout the UK [12] , these data suggest that most GRE have emerged independently at a number of different centres, rather than simply spreading between centres. Furthermore, the wide distribution of the VanA and VanB resistance phenotypes, both of which have been associated with outbreaks [30, 45, 761 , argues that these two genetically distinct, complex resistance mechanisms have arisen in multiple strains in this country. Even though the resistance genes may be transferable, the available data based on the analysis of nosocomial GRE do not provide an easy explanation for these observations and suggest that the true epidemiology of GRE is complex and includes stages outside of the hospital environment. It is this aspect of GRE that is receiving a great deal of attention at present (see below).
A global perspective
Much of the experience gained with GRE in the UK is similar to that reported from other countries. 
An environmental reservoir of GRE
A possible explanation for the distribution of GRE among diverse hospitals in the UK is that these bacteria are endemic in the community and are selected when people are exposed to the various pressures exerted in the hospital environment. The first indication that VanA GRE could be found outside of the hospital environment was published in 1993 by Bates et al. [81] and this aspect has become a major area of research.
Are we what we eat?
In several countries in Europe, VanA enterococci have been isolated in the community and from sewage, the faeces of farm animals, and raw meat for human consumption purchased at retail outlets [82-921. To date, recovery from these sources has not been reported in the USA [93] , although a VanA enterococcus was isolated from a sample of dry dog food [94] . Hence, in Europe at least, these sources are a potential reservoir of GRE that may pass to man and affect public health. Once ingested, these strains may either colonise the human gut, or they may pass transiently, during which time their resistance genes may be passed to the endogenous enterococcal flora.
Obviously it has not been possible to investigate the ability of animal or environmental strains of GRE to colonise man or to transfer resistance genes in vivo, although there is evidence to suggest that this is a likely scenario. In a Belgian study, Van der Auwera et al. failed to isolate GRE from 22 healthy volunteers before oral administration of glycopeptides, although VanA enterococci (confirmed to contain Tn1.546) were isolated from 14 of these volunteers after exposure to glycopeptide antibiotics [9 11 . This suggests that GRE may be present in low numbers in the guts of nonhospitalised subjects, and that these reach detectable frequencies following glycopeptide treatment. A second observation consistent with the possibility that gut carriage of GRE in man may follow exposure to an environmental reservoir is provided by the isolation of GRE from the stools of people who eat meat, but not from those of strict vegetarians [95] . The isolation of VanA enterococci from pet cats and dogs [90, 961 probably indicates that these species are also subject to colonisation by enterococci following ingestion of contaminated food [94] . A reservoir of VanA resistance genes may continue to exist in animal enterococci, despite the current suspension of avoparcin use. Although this suspension makes sense scientifically, and may decrease the direct selective pressure for VanA resistance, the economic pressures faced by the meat production industry will ensure that alternative growth promoting agents will be used in many countries. These alternatives will continue to select for GRE indirectly if the genes that confer resistance to them are linked to glycopeptide resistance genes. In this scenario, the latter genes will persist in the population and the potential remains for transmission to enterococci in man.
VanA resistance and the association with use of avoparcin
Avoparcin has never been licensed for use in the USA [loo] , which suggests that the current problems with GRE in that country may result from the clinical (over)use of vancomycin; teicoplanin is not available in the USA. However, the relative importance of the clinical use of vancomycin and teicoplanin versus the use of avoparcin for animal growth promotion as factors promoting the evolution, selection and dissemination of glycopeptide resistance and GRE in Europe requires further study.
Relatedness of nosocorn ial versus n on -h ospital GRE
Molecular typing studies are necessary to determine the relatedness of VanA GRE from human and non-human sources. Such studies will establish whether exchange of strains occurs, whether some strains are specific either to man or to animals, and whether the strains found in food are also present in the community and hospital patients. Some studies to investigate this have already been undertaken. GRE from different hospitals usually have distinct PFGE patterns as, indeed, may GRE isolated from patients in adjacent beds. Therefore, it is not particularly surprising that there is currently little conclusive evidence for the occurrence of strains 'common to man and other souces. Bates et al. [82] reported that the GRE isolated from two hospital patients and a pig had similar ribotypes, as did two isolates from the stool of a community patient and from sewage. Klare et al. [85] observed similar PFGE patterns in pairs of GRE isolated from (i) minced meat and an outpatient stool, and (ii) minced meat and a clinical specimen, while van Belkum et al. found a particular genotype of GRE in dogs, cats and a human carrier [96] . Recently, identical isolates of GRE have been obtained from turkeys and from the farmer [loll, which suggests that the unrelatedness noted between most isolates in earlier studies may have been because of the lack of a sufficiently close epidemiological relationship between the isolates studied.
As only limited instances of similarity have been noted between the strains of GRE isolated from hospital patients and those isolated from other sources, it seems likely that transfer of plasmids or transposons between enterococci plays a significant role in the dissemination of VanA resistance. Hence, several groups are currently investigating the relationships between genetic elements that confer VanA resistance in enterococci isolated from man and other sources.
Structure of VanA resistance elements
Detection of the vanA gene in GRE from non-human sources (see above) implies the presence of the essential vanH and vanX genes and it has been assumed that these genes are located on elements comparable with Tn1546 [lo]. In the study by Van The author has recently described 24 groups of VanA resistance elements in GRE from UK hospital patients and other sources [104] . Six of these groups were found in GRE from both man and other sources, 10 groups from hospital patients only, and eight groups only from non-human sources. The groups were defined by amplifying 10 overlapping fragments of Tn1546-like elements with primers described by Arthur et Of particular interest was the observation that elements indistinguishable from Tn1546 were more common in enterococci from non-human sources than in strains from hospital patients. This may indicate that VanA elements become more diverse when they enter 'human' enterococci and are subjected to hospital selection pressures. Indeed, variation from Tn1546 is even apparent among the VanA elements of the 'original' GRE isolated from man in the late 1980s; some isolates from the hospital cluster reported by Uttley et al. [l, 451 contain elements indistinguishable from Tn1.546, but others contain Tn1546-like elements that have alterations in orfl and IS elements in the vanX-vanY intergenic region (personal unpublished observations). Variation from Tn1546 was also noted in some French isolates at the time Tn1546 was characterised [lo] .
Recently, Jensen et al. identified a single base change (from G to T) at position 8234 in the vanX gene of some VanA enterococci [103] ; this was the only variation from the published sequence of Tn1546 observed when sequencing fragments of the vanR, vanA and vanX genes [103] . In isolates studied to date, the presence of this mutation appears to correlate with VanA elements defined as 'group D' by Woodford et al. [ 1041 and seems to be associated with GRE isolated from pig faeces and some hospital patients, but not with GRE from the faeces of other animals [ 103, 1041 (personal unpublished observations).
Investigations of the structure of VanA resistance elements are providing tools for dissecting the fine details of VanA epidemiology. The various groups defined may be useful for evolutionary or snapshot epidemiological studies of this resistance. However, their value for long-term epidemiological studies will be compromised if they prove to be highly unstable; transposition of an IS element into, out of, or to a different position within a VanA element would cause the element to be assigned to a different group.
Isolates of a single epidemic strain of VanA E. faecium (EVREM-3) may have VanA elements of distinct groups [104] , which suggests that VanA elements may change more rapidly than more frequently used molecular markers, such as the distribution of SmaI target sites (for PFGE) or rrn operons (for ribotyping). Hence, the stability of the groups requires evaluation.
Does Y,nB resistance occur outside hospitals?
Although An environmental origin for glycopeptide resistance genes?
Vancomycin and teicoplanin are both produced by soil-living bacteria (Amycolatopsis orientalis and Actinoplanes teichomyceticus, respectively) [77] and, not surprisingly, these bacteria are resistant to the action of the agents they produce. In 1990, shortly after the vanA gene was characterised [109] , it was demonstrated that a probe specific for this gene failed to hybridise with DNA from either of the Several major advances in our understanding of glycopeptide resistance followed the development of degenerate PCR primers suitable for amplifying c. 600-bp intragenic fragments of genes (designated ddl) likely to encode enzymes related to D-ala-D-ala ligases [43, 1081 . These primers have recently been modified and used to re-evaluate the possible relationship between the genes present in glycopeptide-producing species and those of GRE [ 1161. Two actinomycetes were studied: A . orientalis (which produces vancomycin) and Streptomyes toyocaensis (which produces an aglycopeptide). The GC contents of the ddl genes obtained from both species (65% and 58%, respectively) differed significantly from those of the vanA (45%) or vanB (48%) genes [116] . This observation may explain the negative hybridisation results noted previously [110] and is consistent with the proposal that there has been no recent direct transfer to enterococci. However, a more distant, evolutionary relationship with the VanA and VanB resistance mechanisms, possibly involving intermediate bacterial genera, has been suggested by comparison of the amino acid sequences of the ligases. Such analysis indicates that enterococcal glycopeptide-resistant ligases are related more closely to the ligases of glycopeptide producers than they are to the ligases of intrinsically resistant genera (Fig. 3) 
Treatment of infections caused by GRE; present and future options
Clinically, the major problem associated with multiresistant enterococci is the lack of available antibiotics with guaranteed bactericidal activity. The array of intrinsic resistance to different antibiotic classes exhibited by enterococci, their relative insensitivity to quinolones, together with their usual tolerance of the bactericidal action of penicillins and glycopeptides [ 117, 1181, means that no single agent shows good activity, even against glycopeptide-sensitive members of this genus. Typically, a cell wall-active agent, such as a penicillin or glycopeptide, is used in combination with an aminoglycoside to exert synergic bactericidal anti-enterococcal activity. However, resistance to either component of the combination results effectively in non-bactericidal monotherapy, which is unsuitable for serious infections such as endocarditis and, possibly, bacteraemia [27] .
As mentioned previously, many GRE isolated in the UK also exhibit high-level resistance to penicillins (strains of E. faecium) and aminoglycosides, particularly those of the VanA phenotype. Thus, should they cause serious disease, these isolates are completely resistant to proven clinical options for therapy and require the use of less-favoured therapies. Therefore, there is a need for new antimicrobial agents with activity against enterococci, including VanA GRE and multiresistant strains. For GRE of the VanB phenotype, teicoplanin plus an aminoglycoside has been suggested as a currently available bactericidal option [119] , and this regimen could probably also be considered for VanC and VanD enterococci as it has proved effective against VanB [69] and VanC [120] enterococci in animal models of endocarditis. However, clinicians should be aware that exposure of VanB enterococci to teicoplanin carries a risk of the emergence of teicoplanin-resistant mutants that express resistance constitutively [7, 691. Although this risk was reduced in an animal model by combination with an aminoglycoside [69] , and so may not be realised clinically, patients treated with this regimen should be monitored carefully.
Several new antimicrobials are in development, including new fluoroquinolones, semi-synthetic vancomycin derivatives, glycylcyclines and oxazolinidones, and many of these exhibit good in-vitro activity against enterococci, including VanA GRE and other multiresistant strains. The reader is referred to a recent review of these agents [ 1211.
Currently, there is considerable interest in the injectable streptogramin combination of quinupristin with dalfopristin ( SynercidTM), which may be licensed for use in the near future. Although isolates of E. faecalis are inherently resistant, this mixture shows good bacteristatic activity against many multiresistant strains of E. faecium. However, concern has been raised that resistance may spread fairly rapidly after the introduction of this agent into clinical use. Transferable resistance to quinupristin with dalfopristin has been reported already in strains of glycopeptide-resistant (VanA phenotype) E. faecium isolated from raw chicken and from hospital patients in the UK [122] . Many authors have indicated the potential for the vanA or vanB gene clusters to emerge in S. aureus, and evidence for this possibility is provided by (i) the number of resistance genes shared by these two genera and, more directly, by (ii) the transfer of VanA resistance to a laboratory strain of methicillin-sensitive S. aureus [14] . Interestingly, E. faecalis strain NCTC 12201, which was used as the donor in the experiments by Noble et al. [14] , contains a VanA element indistinguishable from Tn1.546 (personal unpublished observations). Such elements were present in <lo% of VanA enterococci from UK hospital patients [ 1041. It is possible that the more common VanA elements, many of which have alterations in genes associated with transposition [104] , are able to transfer less readily to other genera than Tn1546 itself. This may explain why VanA resistance has not yet been detected in S. aureus in vivo. A more detailed understanding of the factors affecting transfer of enterococcal glycopeptide determinants is needed to understand and try to avoid the conditions in which transfer to S. aureus is most likely to occur.
Conclusions
Many aspects of the epidemiology of GRE remain unanswered and must be understood if we are to develop rational approaches towards their control. The epidemiology of acquired glycopeptide resistance in enterococci is a complex issue and many factors have contributed to its evolution and dissemination. It seems likely that the next 2-3 years will see major developments in this area as more molecular tools, including DNA sequencing, are applied to large numbers of isolates from diverse sources and hospital clusters. Further insights are likely to be gained into the origins of the various forms of acquired resistance, but it remains to be seen whether these resistances will emerge eventually in S. aureus.
